NeuroVision Imaging Inc. announced today it has received an additional investment from the Alzheimer’s Drug Discovery Foundation (ADDF) – the foundation’s second round of funding to NeuroVision this year – to hasten development of a novel blood-based lab test to provide detection and measurement of biomarkers for Alzheimer’s disease and other dementias before clinical onset.

NeuroVision (neurovision.com) was formed in 2010 and is headquartered in Sacramento, California. The company is dedicated to developing and delivering diagnostic solutions for neurodegenerative and ophthalmological diseases. The company’s team has extensive experience in fluid biomarkers, imaging, and data science.

https://neurovision.com/

Manufacturing

Health Care

Sacramento

Neuro Vision Imaging

Neurovision Imaging Inc. Announces Additional Funding From The Addf To Accelerate Development Of Novel Blood-Based Lab Test To Predict Dementia Before Clinical Onset

Neurovision Imaging Inc. Announces Additional Funding From The Addf To Accelerate Development Of Novel Blood-Based Lab Test To Predict Dementia Before Clinical Onset

Neurovision Imaging Inc. Announces Additional Funding From The Addf To Accelerate Development Of Novel Blood-Based Lab Test To Predict Dementia Before Clinical Onset

Company Info